Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 10/2012

01-10-2012 | Original Article

Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis

Authors: Tallal Younis, Daniel Rayson, Kara Thompson

Published in: Supportive Care in Cancer | Issue 10/2012

Login to get access

Abstract

Background

Variable febrile neutropenia (FN) rates reported with adjuvant TC (taxotere®, cyclophosphamide) and FEC-D (5-flurouracil, epirubicin, cyclophosphamide, docetaxel) outside of clinical trials have precluded definitive recommendations for primary G-CSF (granulocyte colony-stimulating factor) prophylaxis in most jurisdictions. A systematic review and meta-analysis was conducted to assess: (a) FN rates associated with TC and FEC-D without primary G-CSF prophylaxis outside of clinical trial settings, and (b) the potential impact of G-CSF prophylaxis on FN prevention.

Methods

A MEDLINE search was conducted and major conference abstracts were reviewed up to June 15th 2011 to identify all relevant English-language studies. Random- and fixed-effects meta-analysis models were performed.

Results

Nine hundred two patients treated with TC and 1342 with FEC-D from 13 to 9 studies, respectively, were included. The pooled random-effects meta-analysis estimates of FN rates for TC and FEC-D without G-CSF were 29% (95% CI 24–35%) and 31% (95% CI 27–35%), with a 76% (RR = 0.24, 95% CI 0.14–0.41) and 63% (RR = 0.37, 95% CI 0.11–1.24) relative risk reduction with G-CSF, respectively.

Conclusion

In routine clinical practice, TC and FEC-D without G-CSF are associated with FN rates exceeding the 20% threshold for which primary G-CSF prophylaxis is commonly recommended, and are considerably higher than those reported in pivotal clinical trials.
Appendix
Available only for authorised users
Literature
1.
Lyman GH, Rolston KVI (2010) How we treat febrile neutropenia in patients receiving cancer chemotherapy. J Oncol Pract 6(3):149–152PubMedCrossRef
2.
Smith TJ, Khatcheressian J, Lyman GH et al (2006) Update of ASCO practice guideline recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205PubMedCrossRef
3.
Aapro MS, Bohlius J, Cameron DA et al (2011) For the European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8–32PubMedCrossRef
4.
Lathia N, Mittmann N, DeAngelis C et al (2010) Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer 116(3):742–748PubMedCrossRef
5.
Vogel CL, Wojtukiewicz MZ, Carroll RR et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo- controlled phase iii study. J Clin Oncol 23:1178–1184PubMedCrossRef
6.
Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302–2313PubMedCrossRef
7.
Roche H, Fumoleau P, Spielmann M et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 24(36):5664–5671PubMedCrossRef
8.
Jones SE, Savin MA, Holmes FA et al (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24(34):5381–5387PubMedCrossRef
9.
Martin M, Lluch A, Segui M et al (2006) Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 17:1205–1212PubMedCrossRef
10.
Soong D, Haj R, Leung M et al (2009) High rate of febrile neutropaenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide. J Clin Oncol 27:101–102CrossRef
11.
Takabatake D, Taira N, Hara F et al (2009) Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients. Jpn J Clin Oncol 39(8):478–483PubMedCrossRef
12.
Myers R, Higgins B, Myers J et al (2009) Chemotherapy induced febrile neutropenia of docetaxel with cyclophosphamide(TC) for adjuvant therapy of breast cancer in the community-reality check. Cancer Res 69(24 Suppl), Abstract 2092
13.
Chan A, Fu WH, Shih V et al (2011) Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. Support Care Cancer 19(4):497–504, Epub 2010 Mar 17PubMedCrossRef
14.
Caley A, Bertelli G, Rolles M et al (2010) Adjuvant taxane chemotherapy is associated with a significant risk of febrile neutropenia. Eur J Cancer Suppl 8(3):10, Abstract 40CrossRef
15.
Vandenberg T, Younus J, Al-Khayyat S (2010) Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice—a retrospective analysis. Curr Oncol 17(2):2–3PubMedCrossRef
16.
Santos FN, Cruz MR, Cezana L et al (2010) Hematologic toxicity with adjuvant docetaxel and cyclophosphamide in early breast cancer. J Clin Oncol 28, suppl; abstr e11081
17.
McIlroy P, Lumsden G, Haslett K, Macpherson IR (2010) Docetaxel/cyclophosphamide (TC) chemotherapy for early breast cancer: is primary G-CSF prophylaxis necessary? Cancer Res 70(24 Suppl), abstract P5-10-25
18.
Tran M, Simmons CE, Haq R, Brezden CB (2010) A pragmatic review of adjuvant chemotherapy regimens in early-stage breast cancer—hematologic toxicities experienced in a single institution. Cancer Res 70(24 Suppl), abstract P5-10-24
19.
Rayson D, Lutes S, Sellon M, et al. (2011) Population-based incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study. In: St. Gallen Breast Cancer Conference 2011 (16–19 March 2011); (Abstract P332) [available from http://​www.​poster-submission.​com/​search/​sresult]
20.
Kotasek D (2011) Febrile neutropenia rates during docetaxel and cyclophosphamide (TC) adjuvant therapy in early breast cancer (EBC). J Clin Oncol 29, suppl; abstr 1101
21.
Marinho FDS, Lopes MdSdS, Monteiro MMF, Gifoni M (2011) Incidence of febrile neutropenia with adjuvant docetaxel and cyclophosphamide in patients with early breast cancer. J Clin Oncol 29, suppl; abstr e11501
22.
Ngamphaiboon N, Advani PP, O’Connor TL et al (2011) Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in patients with breast cancer: A retrospective analysis. J Clin Oncol 29, suppl; abstr 1134
23.
Soni A, Brufsky A, Jankowitz RC et al (2011) Incidence of febrile neutropenia with docetaxel plus cyclophosphamide in a university-based breast oncology clinic. J Clin Oncol 29, suppl; abstr 9061
24.
25.
26.
27.
Raza S, Welch S, Younus J (2009) Relative dose intensity delivered to patients with early breast cancer: Canadian experience. Curr Oncol 16(6):8–12PubMed
28.
AlKhayyat S, Dent S, Verreault J et al (2009) Incidence of Febrile Neutropenia with Adjuvant FEC-D Therapy in Women with Early Stage Breast Cancer. Cancer Res 69(24 Suppl), Abstract 2087
29.
Gerlier L, Lamotte M, Awada A et al (2010) The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin’s lymphoma. BMC Cancer 10:642PubMedCrossRef
30.
Fraser J, Steele N, Al Zaman A, Yule A (2011) Are patients in clinical trials representative of the general population? Dose intensity and toxicities associated with FE100C-D chemotherapy in a non-trial population of node positive breast cancer patients compared with PACS-01 trial group. Eur J Cancer 47(2):215–220PubMedCrossRef
31.
Madarnas Y, Dent SF, Husain SF et al (2011) Real-world experience with adjuvant FEC-D chemotherapy in four Ontario regional cancer centres. Curr Oncol 18(3):119–125PubMedCrossRef
32.
Newcombe RG (1998) Two-sided confidence intervals for the single proportion: Comparison of seven methods. Stat Med 17:857–872PubMedCrossRef
33.
Borenstein M, Hedges L, Higgins J, Rothstein H (2005) Comprehensive meta analysis. ver. 2. Biostat, Englewood
34.
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRef
35.
Sung L, Nathan PC, Alibhai SM et al (2007) Meta-analysis: effect of prophylactic hematopoietic colony stimulating factors on mortality and outcomes of infection. Ann Intern Med 147:400–411PubMed
36.
Bashir MO, Wu S (2011) Docetaxel-induced neutropenia and neutropenic fever in general and elderly patient population: a meta-analysis. J Clin Oncol 29, suppl; abstr e19729
37.
Chan KK, Trudeau ME, Eisen A et al (2011) The cost-effectiveness of primary prophylaxis with granulocyte colony-stimulating factor in docetaxel-containing adjuvant chemotherapy in early breast cancer: the impact of risk of febrile neutropenia and its mortality. J Clin Oncol 29, suppl; abstr 6086
Metadata
Title
Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis
Authors
Tallal Younis
Daniel Rayson
Kara Thompson
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 10/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-011-1375-6

Other articles of this Issue 10/2012

Supportive Care in Cancer 10/2012 Go to the issue

Review Article

Assessing the social impact of cancer: a review of available tools

Original Article

Using aprepitant as secondary antiemetic prophylaxis for cancer patients with cisplatin-induced emesis

Original Article

A pilot study to examine patient awareness and provider discussion of the impact of cancer treatment on fertility in a registry-based sample of African American women with breast cancer

Original Article

Promoting calcium and vitamin D intake to reduce the risk of osteoporosis in men on androgen deprivation therapy for recurrent prostate cancer

Original Article

Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients

Original Article

Chore or priority? Barriers and facilitators affecting dilator use after pelvic radiotherapy for gynaecological cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits